-+ 0.00%
-+ 0.00%
-+ 0.00%
SirPAD Subgroup Study at VIVA 2026 Focuses on Femoropopliteal PAD in Patients With Claudication
Share
Listen to the news

New results from the SirPAD randomized trial will be presented at VIVA 2026, October 3–6 at Bellagio Las Vegas, focusing on patients with femoropopliteal peripheral artery disease causing intermittent claudication.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending